An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer

Journal of Urology

Volumn 163, Issue 3, 2000, Pages 838-844

  Chertin, Boris ^b   Spitz, Irving M ^b   Lindenberg, Tzina ^b   Algur, Nurit ^b   Zer, Tami ^b   Kuzma, Petr ^b   Moo Young, Alfred J ^b   Catane, Raphael ^b   Farkas, Amicur ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Castration; Drug implants; Male; Neoplasm metastasis; Prostate; Prostatic neoplasms

Indexed keywords

CYPROTERONE ACETATE; FLUTAMIDE; HISTRELIN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG IMPLANT; ENZYME IMMUNOASSAY; HOT FLUSH; HUMAN; IMPOTENCE; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; RADIOIMMUNOASSAY;

EID: 0033953933     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67816-0     Document Type: Article

References (27)

1. Oh, W. K. and Kantoff, P. W.: Management of hormone refractory prostate cancer: current standards and future prospects. J Urol, 160: 1220, 1998
2. Cassileth, B. R., Soloway, M. S., Vogelzang, N. J. et al: Patients' choice of treatment in stage D prostate cancer. Urology, suppl., 33: 57, 1989
3. Catalona, W. J.: Management of cancer of the prostate. N Engl J Med, 331: 996, 1994
4. Crawford, E. D., Eisenberger, M. A., McLeod, D. G. et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med, 321: 419, 1989
5. Crawford, E. D. and DeAntoni, E. P.: Current status of combined androgen blockade: optimal therapy for advanced prostate cancer. J Clin Endocrinol Metab, 80: 1062, 1995
6. Debruyne, F. M., Dijkman, G. A., Lee, D. C. et al: A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer. J Urol, 155: 1352, 1996
7. Dijkman, G. A., del Moral, P. F., Plasman, J. W. et al: A new extra long acting depot preparation of the LH-RH analogue Zoladex. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer. J Steroid Biochem Mol Biol, 37: 933, 1990
8. Kirby, R. S.: Recent advances in the medical management of prostate cancer. Br J Clin Pract, 50: 88, 1996
9. Parmar, H., Phillips, R. H., Lightman, S. L. et al: Randomised controlled study of orchidectomy vs long acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet, 2: 1201, 1985
10. Samdal, F., Vada, K., Lundmo, P. I. et al: Orchidectomy or LHRH-analogue? Which do the patients prefer and what treatment would Norwegian urologists prefer if they had advanced cancer of the prostate? Scand J Urol Nephrol, 25: 197, 1991
11. Santen, R. J., Demers, L. M., Max, D. T. et al: Long term effects of administration of a gonadotropin-releasing hormone superagonist analog in men with prostatic carcinoma. J Clin Endocrinol Metab, 58: 397, 1984
12. Trachtenberg, J.: Progress in complete androgen blockade. Eur Urol, suppl., 31: 8, 1997
13. Walsh, P. C.: Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am, 2: 125, 1975
14. Bowers, C. Y. and Folkers, K.: Gonadotropin-releasing hormone (GnRH), GnRH superagonists, and GnRH antagonists. In: Principles of Pharmacology. Edited by P. Munson, R. Mueller and G. Breese. New York: Chapman and Hall, chapt. 54, pp. 887-895, 1995
15. Clayton, R. N. and Catt, K. J.: Gonadotropin-releasing hormone receptors: characterization, physiological regulation, and relationship to reproductive function. Endocr Rev, 2: 186, 1981
16. Spitz I. M., Chertin, B., Lindenberg, T. et al: Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer. N Engl J Med, 340: 1439, 1999
17. Carter, H. B. and Partin, A. W.: Diagnosis and staging of prostate cancer. In: Campbell's Urology, 7th ed. Edited by P. C. Walsh, A. B. Retik, E. D. Vaughan, Jr. et al. Philadelphia: W. B. Saunders, vol. 2, chapt. 83, pp. 2519-2537, 1998
18. Kuzma, P., Moo-Young, A., Spitz, I. et al: Hydron implant for continuous treatment of prostate cancer: twelve months and beyond. Presented at annual meeting of Biomaterials, Providence, Rhode Island, June 1999
19. Hellman, L., Bradlow, H. L., Freed, S. et al: The effect of flutamide on testosterone metabolism and the plasma levels of androgens and gonadotropins. J Clin Endocrinol Metab, 45: 1224, 1977
20. Knuth, U. A., Hano, R. and Nieschlag, E.: Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men. J Clin Endocrinol Metab, 59: 963, 1984
21. Bergquist, C., Nillius, S. J., Bergh, T. et al: Inhibitory effects on gonadotrophin secretion and gonadal function in men during chronic treatment with a potent stimulatory luteinizing hormone-releasing hormone analogue. Acta Endocrinol (Copenh), 91: 601, 1979
22. Linde, R., Doelle, G. C., Alexander, N. et al: Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. N Engl J Med, 305: 663, 1981
23. Oefelein, M. G.: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol, 160: 1685, 1998
24. Hall, M. C., Fritzsch, R. J., Sagalowsky, A. I. et al: Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology, 53: 898, 1999
25. Bolla, M., Gonzalez, D., Warde, P. et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med, 337: 295, 1997
26. Goldenberg, S. L., Bruchovsky, N., Gleave, M. E. et al: Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology, 45: 839, 1995
27. Anderson, K. E., Spitz, I. M., Sassa, S. et al: Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormone-releasing hormone. N Engl J Med, 311: 643, 1984